Recent Updates
Recently added Catalysts
ACRV Positive Sentiment

Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Monday, August 31, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Acrivon Therapeutics has appointed Michaela Levin, Ph.D., as Chief Business Officer. Levin is an experienced biotechnology executive with a strong background in business development, strategic transactions, and corporate strategy. Her appointment is anticipated to bolster Acrivon's strategic initiatives and growth in the industry.

Market Sentiment Analysis

POSITIVE FACTORS

  • Michaela Levin brings extensive experience in biotechnology.
  • Her background includes business development and corporate strategy.
  • The appointment is expected to enhance Acrivon's strategic initiatives.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+38%
120-day peak, hindsight
Typical move
7.5%
average across 3 past catalysts
Cash runway
~18 mo
Low dilution risk
Lead asset
ACR-2316
Phase 1 · Specific Advanced Solid Tumors

Full Press Release Details

Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy WATERTOWN, Mass., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical

Frequently Asked Questions

Who has been appointed as Chief Business Officer at Acrivon?

Michaela Levin, Ph.D., has been appointed as Chief Business Officer.

What experience does Michaela Levin bring to Acrivon?

Levin brings extensive experience in business development and corporate strategy.

What is Acrivon Therapeutics' focus area?

Acrivon Therapeutics focuses on biotechnology and clinical development.

ShareAdd on Google
Tags: ACRV Viatris Investor Conferences Healthcare Acrivon Therapeutics Michaela Levin Chief Business Officer biotechnology business development
Last updated: Aug 31, 2026

Biotech snapshot

Cash runway
$90M liquidity · $5M/mo burn
~18 mo
Low dilution risk
Lead asset
ACR-2316Phase 1
Specific Advanced Solid Tumors →

Catalyst track record

+38%
best trade around ACRV's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ACRV.

See every catalyst's timing & PoA →